Results 81 to 90 of about 48,361 (234)

A Comprehensive Approach: Addressing Psychological Needs in Gene Therapy for Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) represents a transformative development in the treatment of haemophilia, offering the potential for long‐lasting symptom control after a single administration. Although the scientific and medical aspects of this innovation have been widely studied, its psychological impact remains under‐addressed. Aims This paper
Aida Peyvandi, Ilaria Cutica, Isabella Garagiola, Flora Peyvandi   +3 more
wiley   +1 more source

611. Nonviral Gene Transfer of Factor VII as Alternative Treatment for Hemophilia A [PDF]

, 2005

openalex   +1 more source

Quality of Life and Treatment Satisfaction in People With Haemophilia on Fitusiran Prophylaxis: Evidence From a Subset of ATLAS‐OLE Trial Participants Mainly From India

Haemophilia, EarlyView.
Alok Srivastava, Savita Rangarajan, Cecil Ross, Shariq Ali, Shauna Andersson, Laurel A. Menapace, Marja Puurunen, Marion Afonso   +7 more
wiley   +1 more source

Monitoring of Nonacog Beta Pegol: One‐Stage Clotting Assay With Kaolin Reagent as a Practical Alternative to Chromogenic Methods

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate monitoring of nonacog beta pegol (N9‐GP) is essential to ensure appropriate treatment and to avoid under‐ or overdosing, which may result in clinical complications. The product's extended half‐life, achieved through molecular modification, poses challenges for activity measurement, particularly when using a one‐stage ...
Marie Prudková, Petr Smejkal, Dagmar Chytrá, Jiřina Zavřelová, Gabriela Romanová, Miroslav Penka, Alena Buliková   +6 more
wiley   +1 more source

Hemophilia treatment and transfusion medicine

Zhongguo shuxue zazhi
The improvement of hemophilia treatment is attributed to the development of transfusion medicine, and the discovery of cryoprecipitate has opened up a new era of hemophilia treatment, laying the foundation for the development of modern hemophilia ...
FANG Yunhai, CHENG Yan, ZHANG Xinsheng
doaj   +1 more source

Supporting Patient‐Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model

Haemophilia, EarlyView.
Giovanni Di Minno, Sarah Bigi, Serena Barello, Enrico Ferri Grazzi, Marco Follino, Maria Francesca Mansueto, Mariasanta Napolitano, Rita Carlotta Santoro, Giancarlo Castaman   +8 more
wiley   +1 more source

In Silico Assessment of Limited Blood Sampling Strategies for Individualised Pharmacokinetic‐guided Dosing of Efanesoctocog Alfa in Haemophilia A Patients

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel factor VIII (FVIII) concentrate with a unique molecular design that enables Von Willebrand Factor‐independent clearance in patients with haemophilia A. Limited sampling strategies (LSSs) are necessary to implement accurate pharmacokinetic (PK)‐guided dosing for efanesoctocog alfa in clinical practice.
Jelien den Hollander, Marjon H. Cnossen, Ron A. A. Mathôt   +2 more
wiley   +1 more source

Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment

Haemophilia, EarlyView.
ABSTRACT Introduction The expansion of haemophilia treatment to include non‐factor prophylaxis provides new options with various benefits, risks, administration modes, and device types, necessitating trade‐offs in decision‐making. Aim This study evaluated prophylactic treatment preferences of people with haemophilia and their caregivers, assessing ...
Hui Lu, Travis Gould, Carmine Colavecchia, Joshua Coulter, Lisa J. Wilcox, Joseph C. Cappelleri, Stephanie A. Christopher, Alexis Sohn, Brett Hauber, Álvaro A. Gutiérrez‐Vargas, Nicola Dunn, Pratima Chowdary, Jennifer A. Whitty   +12 more
wiley   +1 more source

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban

Haematologica, 2018
Ida Martinelli, Maria Abbattista, Paolo Bucciarelli, Armando Tripodi, Andrea Artoni, Francesca Gianniello, Cristina Novembrino, Flora Peyvandi   +7 more
doaj   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source